Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

PhoreMost Ltd.. (9/6/22). "Press Release: PhoreMost Enters Multi-project Drug Target Discovery Collaboration with Roche". Cambridge.

Organisations Organisation PhoreMost Ltd.
  Organisation 2 Roche (Group)
Products Product drug target identification
  Product 2 Siteseeker® drug target discovery technology
Index term Index term Roche–PhoreMost: drug target discovery services, 202209– collab €na using Siteseeker platform on pathways nominated by Roche
Persons Person Torbett, Neil (PhoreMost 202203– CEO joined 201701 as CBO befire Activiomics + Piramed Pharma)
  Person 2 Rutter, Ben (Zyme Communications 202209)

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world's leading biotechnology companies. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, toward disease-relevant pathways nominated by Roche. Novel targets identified will be further validated and characterised by Roche’s R&D organisation, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and haematology.

The SITESEEKER® platform is based on PhoreMost’s core proprietary ‘Protein Interference’ (PROTEINi®) technology. PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. SITESEEKER® systematically unmasks new and unanticipated druggable sites across the entire human proteome, directly linking them to useful therapeutic functions.

Dr Neil Torbett, CEO of PhoreMost, said: “This collaboration with Roche is testament to the power and versatility of SITESEEKER, and further validates the potential and broad applications of the platform. We are delighted that Roche has chosen to work with us to enhance its drug discovery pipeline using PROTEINi and SITESEEKER to identify novel targets and unlock the power of protein structure prediction for next generation drug design.”


Notes to editors:

Dr Neil Torbett, CEO, PhoreMost
For a high-resolution image please contact Zyme Communications

Media enquiries PhoreMost:

Dr Ben Rutter
Zyme Communications
Tel: +44 (0)7920 770 935

Dr Neil Torbett
CEO, PhoreMost

About PhoreMost Ltd

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.

Follow PhoreMost on Twitter @PhoreMostLtd and LinkedIn @PhoreMost

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for PhoreMost Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top